Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation
Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s186804
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 1, 2018
Authors
Publisher
Informa UK Limited